๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Tianjin

940 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630Thalassemia, Beta
Bioray Laboratories
Observational
45
Guangzhou, Shenzhen, Nanning, Changsha, Tianjin, Guangxi
2024-12-08
Recruiting
A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
NCT06878625Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
138
Tianjin
2024-12-06
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed โ‰ฅ3 Lines of Therapy.
NCT06733610Autoimmune Hemolytic Anemia, CD19/BCMA CAR T-cells, Universal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2024-12-05
Recruiting
Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke
NCT07115511Stroke
Tianjin Huanhu Hospital
Not applicable
64
Tianjin
2024-12-01
Recruiting
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
NCT07092696Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
34
Tianjin
2024-12-01
Active, closed
Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
NCT06931912Thalassemia Intermedia, Thalassemia Major, Growth Delay, Puberty, Delayed
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
385
Tianjin
2024-12-01
Recruiting
ALI & Pulmonary HA Deposition After SAH
NCT06628531Subarachnoid Haemorrhage (SAH)
Tianjin Medical University
Observational
24
Tianjin
2024-12-01
Not yet open
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist๏ผˆDiphenhydramine๏ผ‰in Advanced and Metastatic Non-Small Cell Lung Cancer
NCT06704620Advanced and Metastatic NSCLC
DrugsDiphenhydramine·Albumin paclitaxel·Pemetrexed·Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 3
430
Tianjin
2024-12
Recruiting
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06933914Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugMY008211A
Wuhan Createrna Science and Technology Co., Ltd
Phase 2/3
120
Tianjin
2024-11-30
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
NCT06895733Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
DrugsPazopanib·Palbociclib
Tianjin Medical University Second Hospital
Phase 1/2
65
Tianjin
2024-11-27
Recruiting
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
NCT06727617Cervical Cancers
Tianjin Medical University Cancer Institute and Hospital
Phase 2
134
Tianjin
2024-11-19
Recruiting
AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
NCT06489197ESCC, Advanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2024-11-16
Recruiting
CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06680388Autoimmune Diseases
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
15
Tianjin
2024-11-15
Active, closed
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
NCT06576921Stomach Neoplasms, Immune Checkpoint Inhibitors
DrugSerplulimab
Xijing Hospital
Phase 2
116
Shijiazhuang, Xi'an, Tianjin
2024-11-15
Active, closed
EPOCH-Economics and Patient Outcomes in China in Haemophilia
NCT07454239Hemophilia
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2024-11-14
Active, closed
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
NCT06717464Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
DrugsCapecitabine·Tislelizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2024-11-12
Recruiting
Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
NCT06721286Intrahepatic Cholangiocarcinoma (Icc)
DrugsGemcitabine·Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
70
Tianjin
2024-11-12
Active, closed
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)
NCT06594146Primary Immune Thrombocytopenia
Keymed Biosciences Co.Ltd
Phase 2
62
Tianjin
2024-11-11
Recruiting
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL
Tianjin Medical University General Hospital
Phase 1/2
90
Tianjin
2024-11-09
Recruiting
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
DrugCC312
CytoCares Inc
Phase EARLY_PHASE1
18
Tianjin
2024-11-08
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
NCT06739395Solid Tumor, Precision Medicine
DrugsVebreltinib Enteric·Dabrafenib·Trametinib·Sacituzumab Govitecan
Tianjin Medical University Second Hospital
Phase 2
300
Tianjin
2024-11-01
Recruiting
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
NCT06695741Severe Aplastic Anemia, Cyclophosphamide Reduced-dose, Immunosuppressive Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
75
Tianjin
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Not yet open
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
NCT06594965Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease
Hansoh BioMedical R&D Company
Phase 2
176
Tianjin
2024-10-30
Recruiting
A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Stroke
NCT06621121Stroke Acute, Tenecteplase, Alteplase
Tianjin Huanhu Hospital
Observational
6,000
Tianjin
2024-10-26
Recruiting
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
NCT06637163Esophageal Squamous Cell Carcinoma
DrugsEtoposide·Carboplatin·Paclitaxel
Shanghai Zhongshan Hospital
Phase 2
100
Shantou, Shenyang, Shanghai, Tianjin, Hangzhou
2024-10-24
Recruiting
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
NCT06613880Aplastic Anemia, TPO Receptor Agonists
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-10-24
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Recruiting
An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours
NCT06695689Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase EARLY_PHASE1
10
Tianjin
2024-10-17
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
200
Nanning, Zhengzhou, Changchun, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
NCT06561880FLT3 Gene Mutation, AML
DrugsGilteritinib·Cytarabine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
66
Tianjin
2024-10-08
Recruiting
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
NCT06775678Lung Cancers, Radiation Treatment for Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2
84
Tianjin
2024-10-01
Recruiting
Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism
NCT06694051Astigmatism
Tianjin Eye Hospital
Not applicable
100
Tianjin
2024-10-01
Recruiting
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
NCT06635681AML (Acute Myelogenous Leukemia)
DrugsDaunorubicin·Cytarabine·Azacitidine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
380
Tianjin
2024-09-29
Recruiting
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
NCT06663007Prostate Cancer, CDK12 Gene Mutation
DrugsEnvafolimab·Disitamab Vedotin
Tianjin Medical University Second Hospital
Phase 1/2
72
Tianjin
2024-09-24
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament
Phase 1/2
171
Shanghai, Tianjin
2024-09-17
Active, closed
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
NCT06500494Advanced Breast Cancer
Pierre Fabre Medicament
Observational
368
Tianjin
2024-09-10
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
NCT07019233Real Time Pressure Controller, Breast Cancer, Albumin Paclitaxel, Peripheral Neuropathy
Tianjin Medical University Cancer Institute and Hospital
Not applicable
118
Tianjin
2024-09-01
Not yet open
Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)
NCT06559072Subarachnoid Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal, Aneurysmal Subarachnoid Hemorrhage, Hemorrhage, Aneurysmal Subarachnoid
DrugAtorvastatin
The George Institute
Phase 3
522
Tianjin
2024-09-01
Recruiting
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
NCT07047560Colorectal Cancer (CRC)
DrugBevacizumab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2024-09-01
Recruiting
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
NCT06560528Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2024-09-01
Recruiting
Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT06852287Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2024-09-01
Not yet open
A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
NCT06500507Relapsed or Refractory Multiple Myeloma
DrugQLS4131
Qilu Pharmaceutical Co., Ltd.
Phase 1
90
Tianjin
2024-08-30
Recruiting
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06932744Paroxysmal Nocturnal Haemoglobinuria (PNH)
DrugsMY008211A·Eculizumab
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
66
Beijing, Tianjin
2024-08-30
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, รœrรผmqi, Wuhan
2024-08-26
Recruiting
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
NCT06479356Non-Hodgkin Lymphoma, Large B-cell Lymphoma
DrugRelma-cel
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
12
Tianjin
2024-08-15
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
Drugs[177Lu]Lu-NeoB·[68Ga]Ga-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
Tianjin
2024-08-14
Recruiting
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
NCT06529250AML
DrugsDaunorubicin·Cytarabine
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
148
Tianjin
2024-08-13
Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06530550Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
51
Tianjin
2024-08-10
Recruiting
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
NCT06530576T-LGL Leukemia, NK-LGL Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
48
Tianjin
2024-08-10
Recruiting
IASO-782 in Autoimmune Hematological Diseases
NCT06534021Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
DrugIASO-782
Shanghai IASO Biotechnology Co., Ltd
Phase 1
16
Wuhan, Tianjin
2024-08-08
Recruiting
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06386302AML, Acute Myeloid Leukemia
DrugsChidamide·Azacitidine·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
184
Tianjin
2024-08-05
Recruiting
Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
NCT06495515CANCER, BRAEST CANCER, Late Frontline
Tianjin Medical University Cancer Institute and Hospital
Phase 2
36
Tianjin
2024-08-01
Recruiting
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962Immune Thrombocytopenia, Treatment
DrugDaratumumab
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-08-01
Recruiting
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
NCT06608732B-cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2024-08-01
Recruiting
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
NCT06463691MCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2024-08-01
Recruiting
Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression
NCT06524505Bipolar Depression
Tianjin Anding Hospital
Not applicable
100
Tianjin
2024-08-01
Recruiting
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
NCT06498154Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
200
Tianjin
2024-07-25
Recruiting
A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.
NCT07070674Acute Graft-versus-Host Disease
Accro Bioscience (Suzhou) Limited
Phase 1
24
Tianjin
2024-07-25
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Active, closed
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
NCT06504199Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
39
Tianjin
2024-07-18
Recruiting
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
NCT06513234Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-07-11
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
DrugsEmpagliflozin·Finerenone
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
NCT06818838Gaucher Disease Type 1
Lingyi Biotech Co., Ltd.
Phase 1/2
12
Guangzhou, Taiyuan, Tianjin
2024-07-05
Active, closed
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469Steroid-refractory Acute Graft Versus Host Disease
DrugRuxolitinib
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
The Effect of Serum Ferritin in irAE
NCT06702566Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
Tianjin Medical University Cancer Institute and Hospital
Not applicable
1,500
Tianjin
2024-07-04
Recruiting
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
NCT06506292Adebrelimab (SHR-1316), XELOX, GC/GEJC
DrugsXelox·Adebrelimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2024-07-01
Recruiting
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
NCT06352008Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
64
Tianjin
2024-07-01
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
DrugsTQB2916·Doxorubicin Hydrochloride·Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·MFOLFOX6·Trastuzumab emtansine
Boehringer Ingelheim
Phase 1/2
768
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT06458595Age-related Macular Degeneration
DrugKH658
Chengdu Origen Biotechnology Co., Ltd.
Phase 1/2
44
Tianjin
2024-06-28
Recruiting
Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography
NCT06654375Stroke Acute, Thrombectomy, Medical Treatment, Large Vessel Occlusion
Tianjin Huanhu Hospital
Not applicable
350
Tianjin
2024-06-25
Recruiting
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
NCT06608342Acute Lymphoblastic Leukemia ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2024-06-25
Recruiting
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
NCT06452602Esophageal Cancer
DrugConcurrent chemoradiotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2024-06-19
Recruiting
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
NCT06454448Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2024-06-15
Recruiting
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
NCT06378242High-risk Non-muscle Invasive Bladder Cancer
DrugDisitamab Vedotin
RemeGen Co., Ltd.
Phase 1/2
24
Guangzhou, Wuhan, Changsha, Nanjing, Chengdu, Tianjin
2024-06-14
Recruiting
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
NCT06389292Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3
486
Tianjin, Hangzhou
2024-06-11
Recruiting
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NCT06481241Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
DrugVenetoclax
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
77
Tianjin
2024-06-10
Recruiting
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
NCT06383871Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd.
Phase 1
233
Tianjin
2024-06-06
Recruiting
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
NCT06481228Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
DrugsOlverembatinib·Venetoclax
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
82
Tianjin
2024-06-04
Not yet open
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
NCT06454435Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsTegafur Gimeracil Oteracil·Sintilimab·Nab-paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 2
158
Tianjin
2024-06
Recruiting
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency
DrugSR604
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT06594640Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
108
Tianjin
2024-05-30
Recruiting
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06417008Non-Squamous Non-Small Cell Lung Cancer
DrugsHS-20117·Aumolertinib
Hansoh BioMedical R&D Company
Phase 2/3
1,080
Tianjin, Hangzhou
2024-05-28
Recruiting
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
NCT06489808Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
89
Tianjin
2024-05-28
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
NCT06421948Peripheral T-cell Lymphoma
Yanyan Liu
Phase 1/2
134
Zhengzhou, Wuhan, Changsha, Chengdu, Tianjin, Hangzhou
2024-05-25
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
DrugEscalation
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
NCT06417567General Anesthesia Gastrointestinal Cancer Surgery
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2024-05-15
Recruiting
MRD-positive AML Clinical Study
NCT07131059AML, Adult
DrugsMitoxantrone·Idarubicin·Avapritinib·Homoharringtonine
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
537
Tianjin
2024-05-11
Recruiting
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06395870B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital
Phase 1
33
Hefei, Tianjin
2024-05-09
Recruiting
A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors
NCT06717022Mesothelin Positive Tumors
Tianjin Medical University Cancer Institute and Hospital
Not applicable
24
Tianjin
2024-05-06
Active, closed
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
NCT06457425MF,PMF,PPV-MF,PET-MF
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2
75
Chengdu, Tianjin
2024-05-06
Not yet open
Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy
NCT05852132Non Proliferative Diabetic Retinopathy(NPDR)
Fei Gao
Not applicable
249
Tianjin
2024-05-05
Rows per page Showing 501–600 of 940
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 940 of those studies with a site in Tianjin.

How many clinical trials are recruiting in Tianjin?

601 of the 940 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 153 have not yet opened recruitment, 162 are active but closed to new participants, and 24 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.